Cook Medical touts paclitaxel-coated stent PAD study results

Cook Medical today touted five-year data from a study into the use of its Zilver PTX paclitaxel-coated stent for peripheral arterial disease (PAD).

The study concluded that there was no increase in long-term all-cause mortality due to paclitaxel after treatment using the Zilver PTX stent compared to traditional angioplasty or a bare-metal stent, according to a release.

Cook Medical’s announcement follows an August 2019 FDA warning to healthcare providers to carefully consider whether to use paclitaxel-coated devices. Use of the devices plunged after a meta-analysis published in the Journal of the American Heart Association last December suggested that PAD patients treated with paclitaxel-coated balloons and stents could be at a higher risk for late death.

Get the full story on our sister site, MassDevice.